Zhitong Finance App News, Tonghua Dongbao (600867.SH) announced that Dong****ing (Hangzhou) Biomedical Co., Ltd. (“Dong****ing”), a wholly-owned subsidiary of the company, recently obtained a clinical trial approval notice from the Drug Evaluation Center (CDE) of the State Drug Administration (CDE) for injectable THDBH120 weight loss indications, agreeing to carry out clinical trials of this product in overweight or obese patients.

According to reports, multiple excitation and long-term synergy are the mainstream research and development trends of peptide weight loss and hypoglycemic agents. Injectable THDBH120 is a glucagon-like peptide-1 (GLP-1) receptor and glucose-insulin-promoting polypeptide (GIP) receptor dual-target agonist. It integrates the two insulin-promoting effects of GLP-1 and GIP into a single polypeptide monomolecule, further enhances metabolic stability through molecular design, and performs synergistically promoted functions such as blood sugar control, weight loss, and lipid metabolism to meet the clinical needs of diabetics with poor treatment effects of single-molecule targets or compound formulations. It is expected to become a more long-term treatment for diabetes and obesity medicines.